A randomized, open-label, dose finding study of the effect of subcutaneous administration of PEGASYS [peginterferon alfa-2a] on tumor response in patients with metastatic malignant melanoma

Trial Profile

A randomized, open-label, dose finding study of the effect of subcutaneous administration of PEGASYS [peginterferon alfa-2a] on tumor response in patients with metastatic malignant melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2010

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 08 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top